Intra-Cellular Therapies, Inc.
ITCI
Rangering i aksjer
#1689
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aksjekurs
$131.87
Sist synkronisert: 2025-04-02
Markedsverdi
$12.68B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
P/S-forhold for Intra-Cellular Therapies, Inc. (ITCI)
P/S-forhold per October 2026 TTM: 20.63
Ifølge Intra-Cellular Therapies, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 20.63. Ved slutten av 2023 hadde selskapet et P/S-forhold på 14.79.
P/S-historikk for Intra-Cellular Therapies, Inc. fra 2013 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 20.63 | 63.10% |
| 2024 | 12.65 | -14.45% |
| 2023 | 14.79 | -25.98% |
| 2022 | 19.98 | -61.62% |
| 2021 | 52.05 | -47.59% |
| 2020 | 99.31 | -99.68% |
| 2019 | 31.24K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | 2.72K | 37.86% |
| 2016 | 1.97K | -90.69% |
| 2015 | 21.20K | 2,320.46% |
| 2014 | 875.93 | 827.98% |
| 2013 | 94.39 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -65.79% |
IN
|
